Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors through Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3

被引：0
|
作者：
Zannetti, A. [1 ]
Iommelli, F. [1 ]
Fonti, R. [1 ]
Papaccioli, A. [1 ]
Sommella, J. [1 ]
Lettieri, A. [1 ]
Bianco, R. [2 ]
Tortora, G. [2 ]
Salvatore, M. [3 ]
Del Vecchio, S. [3 ]
机构：
[1] CNR, Inst Biostruct & Bioimages, Naples, Italy
[2] Univ Naples Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
[3] Univ Naples Federico II, Dept Biomorphol & Funct Sci, Naples, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S187 / S187
页数：1
相关论文
共 50 条
  • [21] Bcl-2, Bcl-xl, and pp32/PHAPI in Resected Non-Small-Cell Lung Cancer Patients
    Schmidt, L. H.
    Kuemmel, A.
    Schuler, M.
    Biesterfeld, S.
    Faldum, A.
    Taube, C.
    Buhl, R.
    Mueller-Tidow, C.
    Wiewrodt, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [22] BCL-2, BCL-XL, AND PP32/PHAPI IN RESECTED NON-SMALL CELL LUNG CANCER PATIENTS
    Schmidt, Lars Henning
    Kuemmel, Andreas
    Martin, Schuler M.
    Biesterfeld, Stefan
    Faldum, Andreas
    Sebastian, Martin
    Taube, Christian
    Buhl, Roland
    Wiewrodt, Rainer
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3479 - 3479
  • [23] Antitumor Activity of BM-1197, a Dual Inhibitor of Bcl-2 and Bcl-xL, in Small Cell Lung Cancer Tumors
    Bai, L.
    Chen, J.
    McEachern, D.
    Liu, L.
    Zhou, H.
    Aguilar, A.
    Yang, C. Y.
    Meagher, J. L.
    Stuckey, J. A.
    Wang, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 125 - 125
  • [24] Modulation of Ca2+signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival
    Rosa, Nicolas
    Speelman-Rooms, Femke
    Parys, Jan B.
    Bultynck, Geert
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (06):
  • [25] Disruption of Sphingosine 1-Phosphate Lyase Confers Resistance to Chemotherapy and Promotes Oncogenesis through Bcl-2/Bcl-xL Upregulation
    Colie, Sandra
    Van Veldhoven, Paul P.
    Kedjouar, Blandine
    Bedia, Carmen
    Albinet, Virginie
    Sorli, Sonia-Caroline
    Garcia, Virginie
    Djavaheri-Mergny, Mojgan
    Bauvy, Chantal
    Codogno, Patrice
    Levade, Thierry
    Andrieu-Abadie, Nathalie
    CANCER RESEARCH, 2009, 69 (24) : 9346 - 9353
  • [26] Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
    Nguyen Tan
    Wong, Maureen
    Nannini, Michelle A.
    Hong, Rebecca
    Lee, Leslie B.
    Price, Stephen
    Williams, Karen
    Savy, Pierre Pascal
    Yue, Peng
    Sampath, Deepak
    Settleman, Jeffrey
    Fairbrother, Wayne J.
    Belmont, Lisa D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 853 - 864
  • [27] Profiling of the Bcl-2/Bcl-XL-binding sites on type 1 IP3 receptor
    Monaco, Giovanni
    Beckers, Marjolein
    Ivanova, Hristina
    Missiaen, Ludwig
    Parys, Jan B.
    De Smedt, Humbert
    Bultynck, Geert
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 428 (01) : 31 - 35
  • [28] Combination of BCL-2/BCL-xL dual inhibitor APG-1252 and chemotherapeutics overcomes resistance to osimertinib in EGFR mutant NSCLC in preclinical models
    Tao, Ran
    Wang, Guangfeng
    Fang, Douglas D.
    Zhai, Guoqin
    Li, Yuanbao
    Lv, Jing
    Wu, Miaoyi
    Ge, Yangfeng
    Zhang, Feifei
    Wen, Danyi
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2020, 80 (16)
  • [29] CDK10, a Potential Predictive Biomarker for Colorectal Cancer, Is Involved in BCL-2 and BCL-XL Mediated-Resistance to Apoptosis
    Weiswald, Louis-Bastien
    Hasan, Mohammad
    Yin, Yaling
    Schaeffer, David F.
    Kennecke, Hagen
    Tai, Isabella T.
    GASTROENTEROLOGY, 2014, 146 (05) : S627 - S627
  • [30] Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
    Tortora, G
    Caputo, R
    Damiano, V
    Caputo, R
    Troiani, T
    Veneziani, BM
    De Placido, S
    Bianco, AR
    Zangemeister-Wittke, U
    Ciardiello, F
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 866 - 871
12345